Schizophrenia

This is our library on scientific research related to CBD, the Endocannabinoid System, other cannabinoids and Schizophrenia. Below you will find a list of conditions for which there are one or more scientific studies of CBD. The source of these scientific studies relates primarily to PubMed, an online service of the U.S. National Library of Medicine.

Important: The studies that are listed by PubMed are for the most part preclinical research. These relate in most cases to animal experiments with isolated CBD (pure CBD) and not fully extracted CBD extract. Although mammals have cell receptors that respond to cannabinoid compounds, the data collected from animal studies are not always 1: 1 applicable to humans. Always check with your physician before starting a new dietary supplement program. Learn more at: The Basics of CBD Oils and Cannabis as a Therapeutic Agent

A critical review of the antipsychotic effects of CBD: 30 years of a translational investigation
Antipsychotic-like effects of cannabidiol and rimonabant
Cannabidiol as a potential treatment for psychosis
Cannabinoids and schizophrenia 
Cannabis Drug Shows Promise in Treating Schizophrenia
Cannabis with high CBD content is associated with fewer psychotic experiences
CBD as an antipsychotic drug 
CBD enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
CBD monotherapy for treatment-resistant schizophrenia
Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?
Improved Social Interaction, Recognition and Working Memory with CBD Treatment in a Prenatal Infection Rat Model.
Marijuana compound treats schizophrenia with few side effects: Clinical trial
Medical use of cannabis. CBD: A new light for schizophrenia?
Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments
Peripheral endocannabinoid system dysregulation in first-episode psychosis

Send this to a friend